Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients
- 1 June 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 38 (6) , 537-545
Abstract
Purpose The aim of this study was to assess the diagnostic and prognostic value of fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT in patients with breast cancer (BC) in the preoperative and the postoperative setting. Patients and methods Between 2011 and 2015, we prospectively enrolled 275 patients (mean age: 53 years) with BC (stage I–III; triple-negative or HER2-positive cancer). One-hundred and forty-nine (54.2%) patients underwent 18F-FDG PET/CT before neoadjuvant therapy and 126 (45.8%) after surgery and before any additional adjuvant therapy. The patients were followed for a median period of 44 (2–57) months. The different effects of PET/CT on the presetting and postsetting phase form a therapeutic and prognostic point of view were assessed by χ2, by Kaplan–Meier, and Cox-regression analyses. Results In the preoperative setting, PET/CT provided additional diagnostic information in 42/149 (28%) patients. In particular, 17/70 (24%) patients at stage III were converted into stage IV and 4/68 (6%) at stage II were upstaged to IV. In the postoperative setting, PET/CT upstaged the disease in both stage IIIC and stage IV in 14/126 (11%) cases. At the end of follow-up, 28/271 (10%) patients died from BC and 40 (15%) had a recurrence of disease. On Kaplan–Meier analysis, patients with a positive PET/CT other than the primary tumor site showed both a worse overall survival and a worse disease-free survival compared with their counterpart (76 vs. 92%; P=0.063 and 65 vs. 100%; P0.05). On multivariate Cox-regression analysis, a positive PET/CT was a significant predictive factor of a poor prognosis in the preoperative setting. The significance was lost in the postoperative setting. Conclusion In the preoperative setting, PET/CT can provide additional diagnostic and prognostic information. Conversely, in the postoperative setting, PET/CT adds diagnostic information, but does not provide any adjunctive prognostic assessment.Keywords
This publication has 19 references indexed in Scilit:
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.European Journal of Nuclear Medicine and Molecular Imaging, 2015
- Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast CancerJNCI: Journal of the National Cancer Institute, 2012
- Clinical impact of 18F-FDG PET/CT on initial staging and therapy planning for breast cancerExperimental and Therapeutic Medicine, 2012
- 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniquesBreast Cancer Research and Treatment, 2011
- Additional Value of PET-CT in Staging of Clinical Stage IIB and III Breast CancerThe Breast Journal, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancerJournal of Surgical Oncology, 2009
- Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene ExpressionJournal of Clinical Oncology, 2008
- Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancerAnnals of Oncology, 2007